Jie He

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/792/publications.pdf

Version: 2024-02-01

280 papers	12,800 citations	50276 46 h-index	36028 97 g-index
295 all docs	295 docs citations	295 times ranked	13719 citing authors

#	Article	IF	Citations
1	Osimertinib in ResectedEGFR-Mutated Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2020, 383, 1711-1723.	27.0	1,042
2	Changing cancer survival in China during 2003â€“15: a pooled analysis of 17 population-based cancer registries. The Lancet Global Health, 2018, 6, e555-e567.	6.3	907
3	Cancer incidence and mortality in China, 2014. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 1-12.	2.2	759
4	Challenges to effective cancer control in China, India, and Russia. Lancet Oncology, The, 2014, 15, 489-538.	10.7	411
5	Annual report on status of cancer in China, 2011. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2015, 27, 2-12.	2.2	405
6	LncRNA profile study reveals a three-lncRNA signature associated with the survival of patients with oesophageal squamous cell carcinoma. Gut, 2014, 63, 1700-1710.	12.1	385
7	Cancer incidence and mortality in China, 2013. Cancer Letters, 2017, 401, 63-71.	7.2	352
8	Mitochondria-Translocated PGK1 Functions as a Protein Kinase to Coordinate Glycolysis and the TCA Cycle in Tumorigenesis. Molecular Cell, 2016, 61, 705-719.	9.7	319
9	KAT2A coupled with the Î±-KGDH complex acts as a histone H3 succinyltransferase. Nature, 2017, 552, 273-277.	27.8	301
10	Cancer registration in China and its role in cancer prevention and control. Lancet Oncology, The, 2020, 21, e342-e349.	10.7	272
11	Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. Journal of Thoracic Oncology, 2020, 15, 816-826.	1.1	272
12	Participation and yield of a population-based colorectal cancer screening programme in China. Gut, 2019, 68, 1450-1457.	12.1	222
13	Prognostic alternative mRNA splicing signature in non-small cell lung cancer. Cancer Letters, 2017, 393, 40-51.	7.2	214
14	Cancer incidence and mortality in China in 2013: an analysis based on urbanization level. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2017, 29, 1-10.	2.2	213
15	The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Cancer Letters, 2020, 470, 95-105.	7.2	193
16	Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China: a comparative risk assessment. The Lancet Global Health, 2019, 7, e257-e269.	6.3	175
17	Joint analysis of three genome-wide association studies of esophageal squamous cell carcinoma in Chinese populations. Nature Genetics, 2014, 46, 1001-1006.	21.4	148
18	Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Nonâ€“Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy. JAMA Oncology, 2021, 7, 1178.	7.1	128

#	Article	IF	Citations
19	Exosomes: New players in cancer. Oncology Reports, 2017, 38, 665-675.	2.6	122
20	Long non-coding RNA NKILA inhibits migration and invasion of non-small cell lung cancer via NF-Î¹B/Snail pathway. Journal of Experimental and Clinical Cancer Research, 2017, 36, 54.	8.6	116
21	Lung Cancer in Peopleâ€™s Republic of China. Journal of Thoracic Oncology, 2020, 15, 1567-1576.	1.1	114
22	Sleep duration and the risk of cancer: a systematic review and meta-analysis including doseâ€“response relationship. BMC Cancer, 2018, 18, 1149.	2.6	105
23	Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. Nature Communications, 2021, 12, 6770.	12.8	105
24	Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncology, The, 2021, 22, 1265-1274.	10.7	102
25	The potential role of N7-methylguanosine (m7G) in cancer. Journal of Hematology and Oncology, 2022, 15, 63.	17.0	94
26	Novel long noncoding RNA NMR promotes tumor progression via NSUN2 and BPTF in esophageal squamous cell carcinoma. Cancer Letters, 2018, 430, 57-66.	7.2	92
27	Clinical characteristics and medical service utilization of lung cancer in China, 2005â€“2014: Overall design and results from a multicenter retrospective epidemiologic survey. Lung Cancer, 2019, 128, 91-100.	2.0	81
28	Development and validation of an immuneâ€related prognostic signature in lung adenocarcinoma. Cancer Medicine, 2020, 9, 5960-5975.	2.8	79
29	WNT/Î²-catenin-suppressed FTO expression increases m6A of c-Myc mRNA to promote tumor cell glycolysis and tumorigenesis. Cell Death and Disease, 2021, 12, 462.	6.3	75
30	Expenditure and financial burden for the diagnosis and treatment of colorectal cancer in China: a hospital-based, multicenter, cross-sectional survey. Chinese Journal of Cancer, 2017, 36, 41.	4.9	74
31	METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N6-methyladenosine-dependent YTHDF binding. Nature Communications, 2021, 12, 3803.	12.8	74
32	Immune signature profiling identified predictive and prognostic factors for esophageal squamous cell carcinoma. OncoImmunology, 2017, 6, e1356147.	4.6	69
33	Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing chemoresistance. Cell Death and Disease, 2018, 9, 759.	6.3	69
34	Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 14	17.0	69
35	Survival Nomogram for Stage IB Non-Small-Cell Lung Cancer Patients, Based on the SEER Database and an External Validation Cohort. Annals of Surgical Oncology, 2021, 28, 3941-3950.	1.5	69
36	Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study. Lancet Public Health, The, 2021, 6, e877-e887.	10.0	69

#	Article	IF	Citations
37	One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study. Lancet Respiratory Medicine,the, 2022, 10, 378-391.	10.7	69
38	The TGFÎ²-induced lncRNA TBILA promotes non-small cell lung cancer progression in vitro and in vivo via cis-regulating HGAL and activating S100A7/JAB1 signaling. Cancer Letters, 2018, 432, 156-168.	7.2	68
39	Survival-associated alternative splicing signatures in esophageal carcinoma. Carcinogenesis, 2019, 40, 121-130.	2.8	66
40	Esophageal cancer: Epidemiology, risk factors and screening. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2021, 33, 535-547.	2.2	64
41	Changes in clinical trials of cancer drugs in mainland China over the decade 2009â€“18: a systematic review. Lancet Oncology, The, 2019, 20, e619-e626.	10.7	63
42	Systemic immuneâ€inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected nonâ€small cell lung cancer. Thoracic Cancer, 2019, 10, 761-768.	1.9	63
43	Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis. Oncotarget, 2018, 9, 13920-13933.	1.8	60
44	Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma. Cancer Letters, 2020, 479, 31-41.	7.2	57
45	The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1209-1219.	6.4	56
46	Immunohistochemical prognostic markers of esophageal squamous cell carcinoma: a systematic review. Chinese Journal of Cancer, 2017, 36, 65.	4.9	55
47	High expression of Collagen Triple Helix Repeat Containing 1 (CTHRC1) facilitates progression of oesophageal squamous cell carcinoma through MAPK/MEK/ERK/FRA-1 activation. Journal of Experimental and Clinical Cancer Research, 2017, 36, 84.	8.6	54
48	Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected esophageal squamous cell carcinoma. Journal of Cancer, 2019, 10, 3188-3196.	2.5	54
49	Breast cancer risk factors and mammographic density among high-risk women in urban China. Npj Breast Cancer, 2018, 4, 3.	5.2	51
50	Comprehensive molecular analyses of a TNF family-based signature with regard to prognosis, immune features, and biomarkers for immunotherapy in lung adenocarcinoma. EBioMedicine, 2020, 59, 102959.	6.1	51
51	A Matched Comparison Study of Uniportal Versus Triportal Thoracoscopic Lobectomy and Sublobectomy for Early-stage Nonsmall Cell Lung Cancer. Chinese Medical Journal, 2015, 128, 2731-2735.	2.3	47
52	The Society for Translational Medicine: clinical practice guidelines for the postoperative management of chest tube for patients undergoing lobectomy. Journal of Thoracic Disease, 2017, 9, 3255-3264.	1.4	47
53	Epidermal Growth Factor Receptor Is a Prognosis Predictor in Patients With Esophageal Squamous Cell Carcinoma. Annals of Thoracic Surgery, 2014, 98, 513-519.	1.3	46
54	Exosomal miR-141 promotes tumor angiogenesis via KLF12 in small cell lung cancer. Journal of Experimental and Clinical Cancer Research, 2020, 39, 193.	8.6	46

#	Article	IF	Citations
55	Medical and nonâ€medical expenditure for breast cancer diagnosis and treatment in China: a multicenter crossâ€sectional study. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 167-178.	1.1	45
56	Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma. Frontiers in Immunology, 2021, 12, 669750.	4.8	45
57	TGF-Î²-induced NKILA inhibits ESCC cell migration and invasion through NF-ÎºB/MMP14 signaling. Journal of Molecular Medicine, 2018, 96, 301-313.	3.9	44
58	Updated experiences with minimally invasive McKeown esophagectomy for esophageal cancer. World Journal of Gastroenterology, 2015, 21, 12873.	3.3	43
59	Epidemiology of Thyroid Cancer: Incidence and Mortality in China, 2015. Frontiers in Oncology, 2020, 10, 1702.	2.8	41
60	A MicroRNA Signature Predicts Survival in Early Stage Small-Cell Lung Cancer Treated with Surgery and Adjuvant Chemotherapy. PLoS ONE, 2014, 9, e91388.	2.5	39
61	Analysis of functional hub genes identifies CDC45 as an oncogene in non-small cell lung cancer - a short report. Cellular Oncology (Dordrecht), 2019, 42, 571-578.	4.4	39
62	Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A doubleâ€blind randomized phase 2 trial. Cancer Medicine, 2021, 10, 1681-1689.	2.8	39
63	Transcriptome profiling of esophageal squamous cell carcinoma reveals a long noncoding RNA acting as a tumor suppressor. Oncotarget, 2015, 6, 17065-17080.	1.8	39
64	Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment. Cancer Letters, 2018, 423, 9-15.	7.2	38
65	Independent and joint associations of blood lipids and lipoproteins with lung cancer risk in Chinese males: A prospective cohort study. International Journal of Cancer, 2019, 144, 2972-2984.	5.1	38
66	Identification of a costimulatory molecule-based signature for predicting prognosis risk and immunotherapy response in patients with lung adenocarcinoma. OncoImmunology, 2020, 9, 1824641.	4.6	38
67	lncTUG1/miR-144-3p affect the radiosensitivity of esophageal squamous cell carcinoma by competitively regulating c-MET. Journal of Experimental and Clinical Cancer Research, 2020, 39, 7.	8.6	38
68	PLAU directs conversion of fibroblasts to inflammatory cancer-associated fibroblasts, promoting esophageal squamous cell carcinoma progression via uPAR/Akt/NF-ÎºB/IL8 pathway. Cell Death Discovery, 2021, 7, 32.	4.7	38
69	Chinese expert consensus on mediastinal lymph node dissection in esophagectomy for esophageal cancer (2017 edition). Journal of Thoracic Disease, 2018, 10, 2481-2489.	1.4	37
70	Enhancement of diagnostic performance in lung cancers by combining CEA and CA125 with autoantibodies detection. OncoImmunology, 2019, 8, e1625689.	4.6	37
71	Transcriptome profiling of lncRNA and co-expression networks in esophageal squamous cell carcinoma by RNA sequencing. Tumor Biology, 2016, 37, 13091-13100.	1.8	36
72	Selection of highâ€risk individuals for esophageal cancer screening: A prediction model of esophageal squamous cell carcinoma based on a multicenter screening cohort in rural China. International Journal of Cancer, 2021, 148, 329-339.	5.1	36

#	Article	IF	Citations
73	m6A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer. Journal of Hematology and Oncology, 2021, 14, 190.	17.0	36
74	The Impact of Postoperative Conformal RadiotherapyÂafter Radical Surgery on Survival andÂRecurrence in Pathologic T3N0M0 Esophageal Carcinoma: AÂPropensity Score-Matched Analysis. Journal of Thoracic Oncology, 2017, 12, 1143-1151.	1.1	35
75	Interferon-inducible lncRNA IRF1-AS represses esophageal squamous cell carcinoma by promoting interferon response. Cancer Letters, 2019, 459, 86-99.	7.2	34
76	Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer. Cancer Biology and Medicine, 2020, 17, 768-781.	3.0	33
77	A Proposal for Combination of Lymph Node Ratio and Anatomic Location of Involved Lymph Nodes for Nodal Classification in Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 1565-1573.	1.1	32
78	Exosomal miR-375-3p breaks vascular barrier and promotes small cell lung cancer metastasis by targeting claudin-1. Translational Lung Cancer Research, 2021, 10, 3155-3172.	2.8	32
79	Characteristics and Surgical Outcomes for Primary Malignant Melanoma of the Esophagus. Scientific Reports, 2016, 6, 23804.	3.3	31
80	Raman spectroscopy as a potential diagnostic tool to analyse biochemical alterations in lung cancer. Analyst, The, 2020, 145, 385-392.	3.5	30
81	A Novel Immune-Related Prognostic Model for Response to Immunotherapy and Survival in Patients With Lung Adenocarcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 651406.	3.7	30
82	KRASâ€G12D mutation drives immune suppression and the primary resistance of antiâ€PDâ€1/PDâ€L1 immunotherapy in nonâ€small cell lung cancer. Cancer Communications, 2022, 42, 828-847.	9.2	29
83	Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer. , 2019, 7, 198.		28
84	Nomogram to Predict Overall Survival for Thoracic Esophageal Squamous Cell Carcinoma Patients After Radical Esophagectomy. Annals of Surgical Oncology, 2019, 26, 2890-2898.	1.5	28
85	Desmoglein-2 modulates tumor progression and osimertinib drug resistance through the EGFR/Src/PAK1 pathway in lung adenocarcinoma. Cancer Letters, 2020, 483, 46-58.	7.2	28
86	Evaluating efficacy of screening for upper gastrointestinal cancer in China: a study protocol for a randomized controlled trial. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2017, 29, 294-302.	2.2	28
87	Medical expenditure for liver cancer in urban China. Journal of Cancer Research and Therapeutics, 2018, 14, 163-170.	0.9	28
88	Comprehensive Analysis Uncovers Prognostic and Immunogenic Characteristics of Cellular Senescence for Lung Adenocarcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 780461.	3.7	28
89	Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer. BMC Medicine, 2022, 20, 187.	5.5	28
90	Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC. Journal of Thoracic Oncology, 2022, 17, 909-920.	1.1	28

#	Article	IF	Citations
91	Medical expenditure for esophageal cancer in China: a 10-year multicenter retrospective survey (2002â€“2011). Chinese Journal of Cancer, 2017, 36, 73.	4.9	27
92	Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma. Nature Communications, 2020, 11, 4878.	12.8	27
93	Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes. Npj Precision Oncology, 2020, 4, 32.	5.4	27
94	The association between fasting blood glucose and the risk of primary liver cancer in Chinese males: a population-based prospective study. British Journal of Cancer, 2017, 117, 1405-1411.	6.4	26
95	Aberrant methylation of EYA4 promotes epithelialâ€mesenchymal transition in esophageal squamous cell carcinoma. Cancer Science, 2018, 109, 1811-1824.	3.9	26
96	Tracheobronchial Adenoid Cystic Carcinoma: 50-Year Experience at the National Cancer Center, China. Annals of Thoracic Surgery, 2019, 108, 873-882.	1.3	26
97	PHD finger protein 5A promoted lung adenocarcinoma progression via alternative splicing. Cancer Medicine, 2019, 8, 2429-2441.	2.8	26
98	The Prognostic Significance of Metabolic Syndrome and a Related Six-lncRNA Signature in Esophageal Squamous Cell Carcinoma. Frontiers in Oncology, 2020, 10, 61.	2.8	26
99	Catastrophic Health Expenditure and Its Determinants Among Households With Breast Cancer Patients in China: A Multicentre, Cross-Sectional Survey. Frontiers in Public Health, 2021, 9, 704700.	2.7	26
100	LAMC1 upregulation via TGFÎ² induces inflammatory cancerâ€associated fibroblasts in esophageal squamous cell carcinoma via NFâ€ÎºBâ€“CXCL1â€“STAT3. Molecular Oncology, 2021, 15, 3125-3146.	4.6	26
101	S100A7 as a potential diagnostic and prognostic biomarker of esophageal squamous cell carcinoma promotes M2 macrophage infiltration and angiogenesis. Clinical and Translational Medicine, 2021, 11, e459.	4.0	26
102	Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma. Cancer Immunology, Immunotherapy, 2022, 71, 2341-2354.	4.2	26
103	Health-related quality of life and utility scores of patients with breast neoplasms in China: A multicenter cross-sectional survey. Breast, 2018, 39, 53-62.	2.2	25
104	H3K36 trimethylation-mediated biological functions in cancer. Clinical Epigenetics, 2021, 13, 199.	4.1	25
105	PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy. Journal of Cancer Research and Clinical Oncology, 2019, 145, 3055-3065.	2.5	24
106	Patterns and predictors of recurrence after radical resection of thymoma. Radiotherapy and Oncology, 2015, 115, 30-34.	0.6	23
107	Associations of PGK1 promoter hypomethylation and PGK1â€mediated PDHK1 phosphorylation with cancer stage and prognosis: a TCGA panâ€cancer analysis. Cancer Communications, 2019, 39, 1-17.	9.2	23
108	International expert consensus on the management of bleeding during VATS lung surgery. Annals of Translational Medicine, 2019, 7, 712-712.	1.7	23

#	Article	IF	Citations
109	Prognostic value of tumor-infiltrating lymphocytes in esophageal cancer: an updated meta-analysis of 30 studies with 5,122 patients. Annals of Translational Medicine, 2020, 8, 822-822.	1.7	23
110	Postoperative Radiotherapy in Pathological T2â€“3N0M0 Thoracic Esophageal Squamous Cell Carcinoma: Interim Report of a Prospective, Phase III, Randomized Controlled Study. Oncologist, 2020, 25, e701-e708.	3.7	23
111	m6A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer. BMC Medicine, 2021, 19, 284.	5.5	23
112	Long non-coding RNA GAS5 is induced by interferons and plays an antitumor role in esophageal squamous cell carcinoma. Cancer Medicine, 2018, 7, 3157-3167.	2.8	22
113	Combined detection of aneuploid circulating tumorâ€derived endothelial cells and circulating tumor cells may improve diagnosis of early stage nonâ€smallâ€cell lung cancer. Clinical and Translational Medicine, 2020, 10, e128.	4.0	22
114	Elevated TOP2A and UBE2C expressions correlate with poor prognosis in patients with surgically resected lung adenocarcinoma: a study based on immunohistochemical analysis and bioinformatics. Journal of Cancer Research and Clinical Oncology, 2020, 146, 821-841.	2.5	22
115	Comprehensive Analysis of the Tumor Microenvironment in Cutaneous Melanoma associated with Immune Infiltration. Journal of Cancer, 2020, 11, 3858-3870.	2.5	22
116	The Society for Translational Medicine: clinical practice guidelines for mechanical ventilation management for patients undergoing lobectomy. Journal of Thoracic Disease, 2017, 9, 3246-3254.	1.4	21
117	Prognostic Impact of Metabolism Reprogramming Markers Acetyl-CoA Synthetase 2 Phosphorylation and Ketohexokinase-A Expression in Non-Small-Cell Lung Carcinoma. Frontiers in Oncology, 2019, 9, 1123.	2.8	21
118	ERO1L promotes IL6/sIL6R signaling and regulates MUC16 expression to promote CA125 secretion and the metastasis of lung cancer cells. Cell Death and Disease, 2020, 11, 853.	6.3	21
119	Initial results from a multi-center population-based cluster randomized trial of esophageal and gastric cancer screening in China. BMC Gastroenterology, 2020, 20, 398.	2.0	21
120	An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma. Signal Transduction and Targeted Therapy, 2020, 5, 182.	17.1	21
121	Prognostic Impact of IGF2BP3 Expression in Patients with Surgically Resected Lung Adenocarcinoma. DNA and Cell Biology, 2021, 40, 316-331.	1.9	21
122	Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China. Journal of Cancer Research and Clinical Oncology, 2022, 148, 943-954.	2.5	21
123	Association between preâ€diagnostic serum albumin and cancer risk: Results from a prospective populationâ€based study. Cancer Medicine, 2021, 10, 4054-4065.	2.8	20
124	Catastrophic health expenditure and its determinants in households with lung cancer patients in China: a retrospective cohort study. BMC Cancer, 2021, 21, 1323.	2.6	20
125	A threeâ€lncRNA signature of pretreatment biopsies predicts pathological response and outcome in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy. Clinical and Translational Medicine, 2020, 10, e156.	4.0	19
126	Lobe-specific Lymph Node Dissection in Clinical Stage IA Solid-dominant Nonâ€“small-cell Lung Cancer: A Propensity Score Matching Study. Clinical Lung Cancer, 2021, 22, e201-e210.	2.6	19

#	Article	IF	Citations
127	A propensity matched comparison of effects between video assisted thoracoscopic single-port, two-port and three-port pulmonary resection on lung cancer. Journal of Thoracic Disease, 2016, 8, 1469-1476.	1.4	18
128	Waist Circumference Might Be a Predictor of Primary Liver Cancer: A Population-Based Cohort Study. Frontiers in Oncology, 2018, 8, 607.	2.8	18
129	The Society for Translational Medicine: the assessment and prevention of venous thromboembolism after lung cancer surgery. Journal of Thoracic Disease, 2018, 10, 3039-3053.	1.4	18
130	Knockdown of KLF5 promotes cisplatinâ€induced cell apoptosis via regulating DNA damage checkpoint proteins in nonâ€small cell lung cancer. Thoracic Cancer, 2019, 10, 1069-1077.	1.9	18
131	Ultrasound for Breast Cancer Screening in High-Risk Women: Results From a Population-Based Cancer Screening Program in China. Frontiers in Oncology, 2019, 9, 286.	2.8	18
132	PD-L1 expression on tumor cells associated with favorable prognosis in surgically resected esophageal squamous cell carcinoma. Human Pathology, 2019, 84, 291-298.	2.0	18
133	RNA N⁶â€methyladenosine modification in the lethal teamwork of cancer stem cells and the tumor immune microenvironment: Current landscape and therapeutic potential. Clinical and Translational Medicine, 2021, 11, e525.	4.0	18
134	The Landscape of Cell and Gene Therapies for Solid Tumors. Cancer Cell, 2021, 39, 7-8.	16.8	18
135	Comparative study of minimally invasive versus open esophagectomy for esophageal cancer in a single cancer center. Chinese Medical Journal, 2014, 127, 747-52.	2.3	18
136	The Society for Translational Medicine: indications and methods of percutaneous transthoracic needle biopsy for diagnosis of lung cancer. Journal of Thoracic Disease, 2018, 10, 5538-5544.	1.4	17
137	Elevated Heterogeneous Nuclear Ribonucleoprotein C Expression Correlates With Poor Prognosis in Patients With Surgically Resected Lung Adenocarcinoma. Frontiers in Oncology, 2020, 10, 598437.	2.8	17
138	TGF-Î²-induced PLEK2 promotes metastasis and chemoresistance in oesophageal squamous cell carcinoma by regulating LCN2. Cell Death and Disease, 2021, 12, 901.	6.3	17
139	Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade. Npj Precision Oncology, 2022, 6, 2.	5.4	17
140	Comparison of shortâ€term outcomes and threeâ€‰yearsurvival between total minimally invasive <scp>M</scp>c<scp>K</scp>eown and dualâ€incision esophagectomy. Thoracic Cancer, 2017, 8, 80-87.	1.9	16
141	Acetyl-macrocalin B, anent-kaurane diterpenoid, initiates apoptosis through the ROS-p38-caspase 9-dependent pathway and induces G2/M phase arrest via the Chk1/2-Cdc25C-Cdc2/cyclin B axis in non-small cell lung cancer. Cancer Biology and Therapy, 2018, 19, 609-621.	3.4	16
142	Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1^{R132H} mutation and may predict better prognosis among glioblastomas without the IDH1 mutation and ATRX loss. Journal of Clinical Pathology, 2018, 71, 702-707.	2.0	16
143	Long-term survival of the middle and lower thoracic esophageal cancer patients after surgical treatment through left or right thoracic approach. Journal of Thoracic Disease, 2018, 10, 2648-2655.	1.4	16
144	A propensity-score matching analysis comparing long-term survival of surgery alone and postoperative treatment for patients in node positive or stage III esophageal squamous cell carcinoma after R0 esophagectomy. Radiotherapy and Oncology, 2019, 140, 159-166.	0.6	16

#	Article	IF	Citations
145	Clinical development of immuno-oncology in China. Lancet Oncology, The, 2020, 21, 1013-1016.	10.7	16
146	Tumor microenvironment characterization identifies two lung adenocarcinoma subtypes with specific immune and metabolic state. Cancer Science, 2020, 111, 1876-1886.	3.9	16
147	Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review. Targeted Oncology, 2021, 16, 425-434.	3.6	16
148	Multi-omics profiling of primary small cell carcinoma of the esophagus reveals RB1 disruption and additional molecular subtypes. Nature Communications, 2021, 12, 3785.	12.8	16
149	Risk factors for gastric cancer: a large-scale, population-based case-control study. Chinese Medical Journal, 2021, 134, 1952-1958.	2.3	16
150	Medical expenditures for colorectal cancer diagnosis and treatment: A 10-year high-level-hospital-based multicenter retrospective survey in China, 2002â˜2011. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 825-837.	2.2	16
151	Plasma extracellular vesicle microRNA profiling and the identification of a diagnostic signature for stage I lung adenocarcinoma. Cancer Science, 2022, 113, 648-659.	3.9	16
152	Lung cancer risk prediction models based on pulmonary nodules: A systematic review. Thoracic Cancer, 2022, 13, 664-677.	1.9	16
153	Sintilimab for the treatment of non-small cell lung cancer. Biomarker Research, 2022, 10, 23.	6.8	16
154	The high expression instead of mutation of p53 is predictive of overall survival in patients with esophageal squamousâ€cell carcinoma: a metaâ€analysis. Cancer Medicine, 2017, 6, 54-66.	2.8	15
155	Long-term outcomes of 307 patients after complete thymoma resection. Chinese Journal of Cancer, 2017, 36, 46.	4.9	15
156	A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients. BMC Medicine, 2020, 18, 232.	5.5	15
157	Elevated SLC2A1 Expression Correlates with Poor Prognosis in Patients with Surgically Resected Lung Adenocarcinoma: A Study Based on Immunohistochemical Analysis and Bioinformatics. DNA and Cell Biology, 2020, 39, 631-644.	1.9	15
158	Highly expressed of SERPINA3 indicated poor prognosis and involved in immune suppression in glioma. Immunity, Inflammation and Disease, 2021, 9, 1618-1630.	2.7	15
159	Effect of socioeconomic status on stage at diagnosis of lung cancer in a hospitalâ€based multicenter retrospective clinical epidemiological study in China, 2005â€“2014. Cancer Medicine, 2017, 6, 2440-2452.	2.8	14
160	Medical expenses of urban Chinese patients with stomach cancer during 2002â€“2011: a hospital-based multicenter retrospective study. BMC Cancer, 2018, 18, 435.	2.6	14
161	Metabolic Syndrome Components and the Risk of Colorectal Cancer: A Population-Based Prospective Study in Chinese Men. Frontiers in Oncology, 2019, 9, 1047.	2.8	14
162	Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma. Cancer Immunology, Immunotherapy, 2021, 70, 3651-3667.	4.2	14

#	Article	IF	Citations
163	Prognostic value of preoperative neutrophil-lymphocyte ratio is superior to platelet-lymphocyte ratio for survival in patients who underwent complete resection of thymic carcinoma. Journal of Thoracic Disease, 2016, 8, 1487-1496.	1.4	13
164	Risk prediction model for lung cancer incorporating metabolic markers: Development and internal validation in a Chinese population. Cancer Medicine, 2020, 9, 3983-3994.	2.8	13
165	Prognostic Impact of PCK1 Protein Kinase Activity-Dependent Nuclear SREBP1 Activation in Non-Small-Cell Lung Carcinoma. Frontiers in Oncology, 2021, 11, 561247.	2.8	13
166	Comprehensive Analysis of Ferroptosis Regulators in Lung Adenocarcinomas Identifies Prognostic and Immunotherapy-Related Biomarkers. Frontiers in Molecular Biosciences, 2021, 8, 587436.	3.5	13
167	Availability of anticancer biosimilars in 40 countries. Lancet Oncology, The, 2020, 21, 197-201.	10.7	13
168	Nomogram and recursive partitioning analysis to predict overall survival in patients with stage IIB-III thoracic esophageal squamous cell carcinoma after esophagectomy. Oncotarget, 2016, 7, 55211-55221.	1.8	13
169	Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis. Frontiers in Immunology, 2022, 13, 783495.	4.8	13
170	Lipid metabolismâ€“related lncRNA SLC25A21â€AS1 promotes the progression of oesophageal squamous cell carcinoma by regulating the NPM1/câ€Myc axis and SLC25A21 expression. Clinical and Translational Medicine, 2022, 12, .	4.0	13
171	Prognostic factors in curatively resected pathological stage I lung adenocarcinoma. Journal of Thoracic Disease, 2017, 9, 5267-5277.	1.4	12
172	Solitary fibrous tumors of the pleura: A single center experience at National Cancer Center, China. Thoracic Cancer, 2018, 9, 1763-1769.	1.9	12
173	Monoacylglycerol Lipase Knockdown Inhibits Cell Proliferation and Metastasis in Lung Adenocarcinoma. Frontiers in Oncology, 2020, 10, 559568.	2.8	12
174	An initial screening strategy based on epidemiologic information in esophageal cancer screening: a prospective evaluation in a community-based cancer screening cohort in rural China. Gastrointestinal Endoscopy, 2021, 93, 110-118.e2.	1.0	12
175	Construction and Comprehensive Analyses of a METTL5-Associated Prognostic Signature With Immune Implication in Lung Adenocarcinomas. Frontiers in Genetics, 2020, 11, 617174.	2.3	12
176	Development and Validation of a Nomogram Prognostic Model for Resected Limited-Stage Small Cell Lung Cancer Patients. Annals of Surgical Oncology, 2021, 28, 4893-4904.	1.5	12
177	Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 3713-3736.	2.8	12
178	Anlotinib in chemotherapy-refractory metastatic esophageal squamous cell carcinoma (ESCC): A randomized, double-blind, multicenter phase II trial.. Journal of Clinical Oncology, 2019, 37, 95-95.	1.6	12
179	Experiences in the management of anastomotic leakages and analysis of the factors affecting leakage healing in patients with esophagogastric junction cancer. Journal of Thoracic Disease, 2017, 9, 386-391.	1.4	11
180	Healthâ€related quality of life in patients with esophageal cancer or precancerous lesions assessed by EQâ€5D: A multicenter crossâ€sectional study. Thoracic Cancer, 2020, 11, 1076-1089.	1.9	11

#	Article	IF	Citations
181	Association of phosphoenolpyruvate carboxykinase 1 protein kinase activity-dependent sterol regulatory element-binding protein 1 activation with prognosis of oesophageal carcinoma. European Journal of Cancer, 2021, 142, 123-131.	2.8	11
182	Utility of isocitrate dehydrogenase 1 as a serum protein biomarker for the early detection of nonâ€smallâ€cell lung cancer: A multicenter in vitro diagnostic clinical trial. Cancer Science, 2020, 111, 1739-1749.	3.9	11
183	Identification and validation of cellular senescence patterns to predict clinical outcomes and immunotherapeutic responses in lung adenocarcinoma. Cancer Cell International, 2021, 21, 652.	4.1	11
184	Prognostic value of preoperative serum lactate dehydrogenase in thymic carcinoma. Journal of Thoracic Disease, 2016, 8, 2464-2472.	1.4	10
185	RNA editing is induced by type I interferon in esophageal squamous cell carcinoma. Tumor Biology, 2017, 39, 101042831770854.	1.8	10
186	A prognostic nomogram for overall survival after neoadjuvant radiotherapy or chemoradiotherapy in thoracic esophageal squamous cell carcinoma: a retrospective analysis. Oncotarget, 2017, 8, 41102-41112.	1.8	10
187	Acetyl-macrocalin B suppresses tumor growth in esophageal squamous cell carcinoma and exhibits synergistic anti-cancer effects with the Chk1/2 inhibitor AZD7762. Toxicology and Applied Pharmacology, 2019, 365, 71-83.	2.8	10
188	Liquid biopsy for esophageal cancer: Is detection of circulating cellâ€free DNA as a biomarker feasible?. Cancer Communications, 2021, 41, 3-15.	9.2	10
189	Treatment outcomes of patients with tracheobronchial mucoepidermoid carcinoma compared with those with adenoid cystic carcinoma. European Journal of Surgical Oncology, 2020, 46, 1888-1895.	1.0	10
190	Society for Translational Medicine Expert consensus on the selection of surgical approaches in the management of thoracic esophageal carcinoma. Journal of Thoracic Disease, 2019, 11, 319-328.	1.4	10
191	No expenditure difference among patients with liver cancer at stage I-IV: Findings from a multicenter cross-sectional study in China. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 516-529.	2.2	10
192	ERAP2 Is Associated With Immune Infiltration and Predicts Favorable Prognosis in SqCLC. Frontiers in Immunology, 2021, 12, 788985.	4.8	10
193	The membrane-bound and soluble form of melanotransferrin function independently in the diagnosis and targeted therapy of lung cancer. Cell Death and Disease, 2020, 11, 933.	6.3	9
194	High <scp>MAF</scp> of <scp>EGFR</scp> mutations and high ratio of <scp>T790M sensitizing mutations</scp> in <scp>ctDNA</scp> predict better thirdâ€generation <scp>TKI</scp> outcomes. Thoracic Cancer, 2020, 11, 1503-1511.	1.9	9
195	Patterns and trends of cancer incidence in children and adolescents in China, 2011â€“2015: A populationâ€based cancer registry study. Cancer Medicine, 2021, 10, 4575-4586.	2.8	9
196	Identification of a Prognostic Immune Signature for Esophageal Squamous Cell Carcinoma to Predict Survival and Inflammatory Landscapes. Frontiers in Cell and Developmental Biology, 2020, 8, 580005.	3.7	9
197	A Model Predicting Lymph Node Status for Patients with Clinical Stage T1aN0-2M0 Nonsmall Cell Lung Cancer. Chinese Medical Journal, 2017, 130, 398-403.	2.3	9
198	The therapeutic significance of the novel photodynamic material TPE-IQ-2O in tumors. Aging, 2021, 13, 1383-1409.	3.1	9

#	Article	IF	Citations
199	Outcomes and experience of anatomical partial lobectomy. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 637-647.e1.	0.8	9
200	Mapping of Lymph Node Metastasis From Thoracic Esophageal Cancer: A Retrospective Study. Annals of Surgical Oncology, 2022, 29, 5681-5688.	1.5	9
201	The impact of operative approaches on outcomes of middle and lower third esophageal squamous cell carcinoma. Journal of Thoracic Disease, 2016, 8, 3588-3595.	1.4	8
202	The therapeutic effects of Longikaurin A, a natural ent-kauranoid, in esophageal squamous cell carcinoma depend on ROS accumulation and JNK/p38 MAPK activation. Toxicology Letters, 2017, 280, 106-115.	0.8	8
203	Sequencing a super multiple synchronous lung cancer reveals a novel variant in driver gene ARID1B. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, e185-e191.	0.8	8
204	Society for Translational Medicine Expert Consensus on the prevention and treatment of postoperative pulmonary infection in esophageal cancer patients. Journal of Thoracic Disease, 2018, 10, 1050-1057.	1.4	8
205	Society for Translational Medicine Expert Consensus on the preoperative assessment of circulatory and cardiac functions and criteria for the assessment of risk factors in patients with lung cancer. Journal of Thoracic Disease, 2018, 10, 5545-5549.	1.4	8
206	Immune signature of tumor-infiltrating immune cells predicts the prognosis and therapeutic effects in squamous cell carcinoma. International Immunopharmacology, 2020, 87, 106802.	3.8	8
207	Presentation of EGFR mutations in 162 family probands with multiple primary lung cancer. Translational Lung Cancer Research, 2021, 10, 1734-1746.	2.8	8
208	Associations between female lung cancer risk and sex steroid hormones: a systematic review and meta-analysis of the worldwide epidemiological evidence on endogenous and exogenous sex steroid hormones. BMC Cancer, 2021, 21, 690.	2.6	8
209	Improved esophageal squamous cell carcinoma screening effectiveness by riskâ€stratified endoscopic screening: evidence from highâ€risk areas in China. Cancer Communications, 2021, 41, 715-725.	9.2	8
210	Preoperative systemic immune-inflammation index predicts survival and recurrence in patients with resected primary pulmonary sarcomatoid carcinoma. Translational Lung Cancer Research, 2021, 10, 18-31.	2.8	8
211	Methionine oxidation of CLK4 promotes the metabolic switch and redox homeostasis in esophageal carcinoma via inhibiting MITF selective autophagy. Clinical and Translational Medicine, 2022, 12, e719.	4.0	8
212	<scp>BMI</scp> changes and the risk of lung cancer in male neverâ€smokers: A prospective cohort study. Cancer Medicine, 2022, 11, 1336-1346.	2.8	8
213	The association between fasting blood glucose trajectory and cancer risk in Chinese population without diabetes. International Journal of Cancer, 2020, 147, 958-966.	5.1	7
214	Systematic profiling of immune signatures identifies prognostic predictors in lung adenocarcinoma. Cellular Oncology (Dordrecht), 2020, 43, 681-694.	4.4	7
215	Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial. BMC Cancer, 2020, 20, 278.	2.6	7
216	The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma. Cancer Biology and Medicine, 2021, 18, 562-568.	3.0	7

#	Article	IF	Citations
217	Tumor mutation score is more powerful than tumor mutation burden in predicting response to immunotherapy in non-small cell lung cancer. Cancer Immunology, Immunotherapy, 2021, 70, 2367-2378.	4.2	7
218	Effects of cancer treatment on household impoverishment: a multicentre cross-sectional study in China. BMJ Open, 2021, 11, e044322.	1.9	7
219	Integrative analysis and experiments to explore angiogenesis regulators correlated with poor prognosis, immune infiltration and cancer progression in lung adenocarcinoma. Journal of Translational Medicine, 2021, 19, 361.	4.4	7
220	Medical expenditure for lung cancer in China: a multicenter, hospital-based retrospective survey. Cost Effectiveness and Resource Allocation, 2021, 19, 53.	1.5	7
221	Integrated bioinformatics analysis of chromatin regulator EZH2 in regulating mRNA and lncRNA expression by ChIP sequencing and RNA sequencing. Oncotarget, 2016, 7, 81715-81726.	1.8	7
222	A study protocol of population-based cancer screening cohort study on esophageal, stomach and liver cancer in rural China. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 540-546.	2.2	7
223	The TGFÎ²-Induced Long Non-coding RNA TBULC Promotes the Invasion and Migration of Non-small Cell Lung Cancer Cells and Indicates Poor Prognosis. Frontiers in Oncology, 2019, 9, 1340.	2.8	6
224	Development of a risk score for colorectal cancer in Chinese males: A prospective cohort study. Cancer Medicine, 2020, 9, 816-823.	2.8	6
225	Managing a radiotherapy center safely and efficiently using risk-adaptive strategies during coronavirus disease pandemic: Experience from national cancer center of China. Radiotherapy and Oncology, 2020, 148, 243-244.	0.6	6
226	Loss of SUSD2 expression correlates with poor prognosis in patients with surgically resected lung adenocarcinoma. Journal of Cancer, 2020, 11, 1648-1656.	2.5	6
227	The landscape of m6A regulators in small cell lung cancer: molecular characteristics, immuno-oncology features, and clinical relevance. Molecular Cancer, 2021, 20, 122.	19.2	6
228	Comparison of surgical difficulty in patients with resectable non-small cell lung cancer under different neoadjuvant treatment modes: a retrospective cohort study. Journal of Thoracic Disease, 2021, 13, 5604-5616.	1.4	6
229	High S phase kinaseâ€'associated protein 2 expression is a potential prognostic biomarker for glioma. Oncology Letters, 2020, 20, 2788-2796.	1.8	6
230	The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors. Frontiers in Oncology, 2022, 12, 843299.	2.8	6
231	Cross-talk of pyroptosis and tumor immune landscape in lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 4423-4444.	2.8	6
232	Society for Translational Medicine expert consensus on training and certification standards for surgeons and assistants in minimally invasive surgery for lung cancer. Journal of Thoracic Disease, 2018, 10, 5666-5672.	1.4	5
233	Translational value of IDH1 and DNA methylation biomarkers in diagnosing lung cancers: a novel diagnostic panel of stage and histology-specificity. Journal of Translational Medicine, 2019, 17, 430.	4.4	5
234	The combination of novel immune checkpoints HHLA2 and ICOSLG: A new system to predict survival and immune features in esophageal squamous cell carcinoma. Genes and Diseases, 2022, 9, 415-428.	3.4	5

#	Article	IF	Citations
235	Development of a predictive nomogram for cause-specific mortality in surgically resected early-stage oesophageal cancer: a Surveillance, Epidemiology, and End Results (SEER) analysis. Journal of Thoracic Disease, 2020, 12, 2583-2594.	1.4	5
236	Healthâ€related quality of life of patients with colorectal neoplasms in China: A multicenter crossâ€sectional survey. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1197-1207.	2.8	5
237	Ubiquitination Destabilizes Protein Sphingosine Kinase 2 to Regulate Glioma Malignancy. Frontiers in Cellular Neuroscience, 2021, 15, 660354.	3.7	5
238	Over-expression of small ubiquitin-like modifier proteases 1 predicts chemo-sensitivity and poor survival in non-small cell lung cancer. Chinese Medical Journal, 2014, 127, 4060-5.	2.3	5
239	An immune-related lncRNA signature predicts prognosis and adjuvant chemotherapeutic response in patients with small-cell lung cancer. Cancer Cell International, 2021, 21, 691.	4.1	5
240	Society for Translational Medicine expert consensus on the use of antibacterial drugs in thoracic surgery. Journal of Thoracic Disease, 2018, 10, 6356-6374.	1.4	4
241	Lung cancer imaging methods in China from 2005 to 2014: A national, multicenter study. Thoracic Cancer, 2019, 10, 708-714.	1.9	4
242	Solid Nodule Appearance as a Predictor of Tumor Spread Through Air Spaces in Patients with Lung Adenocarcinoma: A Propensity Score Matching Study . Cancer Management and Research, 2020, Volume 12, 8197-8207.	1.9	4
243	ECCParaCorp: a cross-lingual parallel corpus towards cancer education, dissemination and application. BMC Medical Informatics and Decision Making, 2020, 20, 122.	3.0	4
244	The prognostic value of tumor deposits and the impact on the TNM classification system in esophageal cancer patients. Journal of Surgical Oncology, 2021, 123, 891-903.	1.7	4
245	Development and external validation of a composite immune-clinical prognostic model associated with EGFR mutation in East-Asian patients with lung adenocarcinoma. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110069.	3.2	4
246	Two-year follow-up of single PD-1 blockade in neoadjuvant resectable NSCLC.. Journal of Clinical Oncology, 2021, 39, 8522-8522.	1.6	4
247	Intensity modulated radiation therapy may improve survival for tracheal-bronchial adenoid cystic carcinoma: A retrospective study of 133 cases. Lung Cancer, 2021, 157, 116-123.	2.0	4
248	Menstrual factors, reproductive history, and risk of lung cancer: a multi-center population-based cohort study in Chinese females. Translational Lung Cancer Research, 2021, 10, 3912-3928.	2.8	4
249	Dumbbell-Shaped Jugular Foramen Tumors Extending to the Neck: Surgical Considerations Based on Imaging Findings. World Neurosurgery, 2017, 104, 14-23.	1.3	3
250	Rabdocoestin B exhibits antitumor activity by inducing G2/M phase arrest and apoptosis in esophageal squamous cell carcinoma. Cancer Chemotherapy and Pharmacology, 2018, 81, 469-481.	2.3	3
251	A systematic review of recommendations on screening strategies for breast cancer due to hereditary predisposition: Who, When, and How?. Cancer Medicine, 2021, 10, 3437-3448.	2.8	3
252	Tumorâ€infiltrating CD8⁺ T cell is prognostic and predicts adjuvant chemotherapy benefit in patients with limitedâ€stage small cell esophageal carcinoma. Clinical and Translational Medicine, 2021, 11, e456.	4.0	3

#	Article	IF	Citations
253	Development and validation of m6A RNA methylation regulators-based signature in lung adenocarcinoma. Chinese Medical Journal, 2021, 134, 2128-2130.	2.3	3
254	Severe hypoglycemia and finger clubbing in a patient with a BRCA1 mutation in a solitary fibrous tumor: a case report. Annals of Translational Medicine, 2021, 9, 1093-1093.	1.7	3
255	Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer. Frontiers in Immunology, 2021, 12, 745769.	4.8	3
256	Recurrence risk stratification based on a competing-risks nomogram to identify patients with esophageal cancer who may benefit from postoperative radiotherapy. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110619.	3.2	3
257	Pan-cancer analysis combined with experiments explores the oncogenic role of spindle apparatus coiled-coil protein 1 (SPDL1). Cancer Cell International, 2022, 22, 49.	4.1	3
258	Collision tumor of the esophagus: a report of five cases. Chinese Medical Journal, 2020, 133, 2386-2388.	2.3	2
259	Multi-region sequencing reveals genetic correlation between esophageal squamous cell carcinoma and matched cell-free DNA. Cancer Genetics, 2021, 258-259, 93-100.	0.4	2
260	Adjuvant immunotherapy in resected esophageal squamous cell carcinoma: a gospel to the non-pCRs. Signal Transduction and Targeted Therapy, 2021, 6, 314.	17.1	2
261	A novel recurrence-associated metabolic prognostic model for risk stratification and therapeutic response prediction in patients with stage I lung adenocarcinoma. Cancer Biology and Medicine, 2021, 18, 734-749.	3.0	2
262	Effect of the TGFÎ² induced lncRNA TBILA on non-small cell lung cancer progression by regulating HGAL and binding with S100A7.. Journal of Clinical Oncology, 2018, 36, e24203-e24203.	1.6	2
263	Ferroptosis Characterization in Lung Adenocarcinomas Reveals Prognostic Signature With Immunotherapeutic Implication. Frontiers in Cell and Developmental Biology, 2021, 9, 743724.	3.7	2
264	Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for stage I lung adenocarcinoma. Translational Lung Cancer Research, 2021, 11, 0-0.	2.8	2
265	Nivolumab plus ipilimumab: a potential regimen to rewrite treatment guidelines for ESCC. Signal Transduction and Targeted Therapy, 2022, 7, .	17.1	2
266	<scp>PSC</scp> subtyping based on <scp>TTF</scp>â€‘1 and p40 expression reveals distinct molecular characteristics and therapeutic strategies. International Journal of Cancer, 2022, 151, 717-729.	5.1	2
267	Esophageal Squamous Cell Carcinoma Involving the Lip, Back and Hip. Journal of Thoracic Oncology, 2019, 14, 1672-1674.	1.1	1
268	MiRACLe: an individual-specific approach to improve microRNA-target prediction based on a random contact model. Briefings in Bioinformatics, 2021, 22, .	6.5	1
269	A Multi-Center Validated Subtyping Model of Esophageal Cancer Based on Three Metabolism-Related Genes. Frontiers in Oncology, 2021, 11, 772145.	2.8	1
270	Burchellin and its stereoisomers: total synthesis, structural elucidation and antiviral activity. Organic and Biomolecular Chemistry, 2020, 18, 9081-9087.	2.8	1

#	Article	IF	Citations
271	Choline Kinase Alpha2 Promotes Lipid Droplet Lipolysis in Non-Small-Cell Lung Carcinoma. Frontiers in Oncology, 2022, 12, 848483.	2.8	1
272	Response to comment on â€˜Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinomaâ€™. Cancer Letters, 2020, 494, 5-6.	7.2	0
273	Features in genomics and tumor immune microenvironment in NSCLC treated with neoadjuvant PD-1 blockade.. Journal of Clinical Oncology, 2021, 39, 9063-9063.	1.6	0
274	Abstract 772: A novel recurrence-associated metabolic prognostic model for risk stratification and therapeutic responses prediction in patients with stage I lung adenocarcinoma. , 2021, , .		0
275	553Stage at diagnosis for six major cancers in China with comparison to the United States. International Journal of Epidemiology, 2021, 50, .	1.9	0
276	Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer. Frontiers in Immunology, 2021, 12, 782106.	4.8	0
277	National Cancer Data Linkage Platform of China: Design, Methods, and Application.. China CDC Weekly, 2022, 4, 271-275.	2.3	0
278	Abstract 5349: Single-cell analysis sheds light on the resistance mechanisms of a novel pan-HER inhibitor, pyrotinib, in non-small cell lung cancer. Cancer Research, 2022, 82, 5349-5349.	0.9	0
279	Abstract 5692: Tissue specificity of chromosome aneuploidy correlates with BRCA-associated cancer risk. Cancer Research, 2022, 82, 5692-5692.	0.9	0
280	Non-invasive cell-free DNA monitoring for predicting the response to neoadjuvant immunotherapy in locally advanced esophageal squamous cell carcinoma.. Journal of Clinical Oncology, 2022, 40, e16040-e16040.	1.6	0